Is 300mg Valproic Acid Available in the Philippines?
Yes, 300 mg valproic acid tablets are available as a standard formulation. According to FDA labeling, valproic acid is manufactured in multiple strengths including 300 mg tablets 1. This formulation is widely distributed internationally as a standard antiepileptic drug dose.
Formulation Details
Valproic acid 300 mg is available in several formulations:
- Plain (immediate-release) tablets - Standard formulation with rapid absorption 2, 3
- Enteric-coated tablets - Delayed-release formulation to reduce gastrointestinal irritation 2, 3
- Extended-release preparations - Controlled-release formulations allowing less frequent dosing 2, 4
The 300 mg strength represents a common mid-range dose that fits within standard dosing algorithms. According to FDA guidelines, valproic acid capsules should be swallowed whole without chewing to avoid local irritation 1.
Clinical Context for the Philippines
Valproic acid is specifically recommended for use in low- and middle-income countries (LAMICs), which includes the Philippines. WHO guidelines explicitly list valproic acid as one of the standard antiepileptic drugs that should be offered for convulsive epilepsy in non-specialized healthcare settings 5. The 300 mg formulation allows for flexible dosing adjustments in the typical therapeutic range of 10-60 mg/kg/day 1.
Practical Dosing Considerations
The 300 mg tablet strength is particularly useful because:
- It allows for incremental dose adjustments (5-10 mg/kg/week increases) as recommended 1
- Multiple tablets can achieve target doses for most adult patients (typically 1000-2000 mg/day)
- It's suitable for both monotherapy and adjunctive therapy regimens 1
Important caveat: While the 300 mg formulation exists globally, local availability in specific Philippine pharmacies should be confirmed directly, as drug distribution can vary by region and supplier. However, as a WHO-recommended essential medication for LAMICs, valproic acid in standard doses including 300 mg should be accessible through major pharmaceutical channels in the Philippines 5.